摘要:
The invention relates to compositions comprising one or more of the following compounds designated WS-1627A, WS-1627B, WS-1627C and WS-1627D, or salts thereof: WS-1627A, WS-1627B and WS-1627D are in fact known antibiotics, but WS-1627C is a new epimer of the antibiotic KA-3093. The compositions are useful both for preventing or treating swine dysentery and as animal growth promotants. There is also provided a process for preparing WS-1627A, WS-1627B, WS-1627C and WS-1 627D which comprises culturing a WS-1627A, WS-1627B, WS-1627C and/or WS-1627D producing strain belonging to the genus Streptomyces in a nutrient medium and recovering the product.
摘要:
The invention relates to a new compound, designated FR-900451, and pharmaceutically acceptable salts thereof. The compound has antimicrobial properties and is effective in the treatment of various infectious diseases in both human beings and animals. There is also provided a process for preparing FR-900451 compound which comprises culturing a FR-900451 producing strain belonging to the genus Streptomyces in a nutrient medium. Pharmaceutical compositions comprising FR-900451 as an active ingredient are also described.
摘要:
Compounds of the formula: wherein R 1 is hydrogen, alkanoyloxy or alkenoyloxy; R 2 is alkyl or alkenyl; R 3 and R 4 are each hydrogen, lower alkyl, hydroxy(lower)alkyl, ar(lower) alkyl, esterified carboxy(lower)alkyl, carboxy-(lower)alkyl, protected amino(lower)alkyl or amino(lower)alkyl; R 5 is hydrogen, hydroxy(lower)alkyl, protected amino-(lower)alkyl, amino(lower)alkyl, carboxy(lower)alkyl or esterified carboxy(lower)alkyl; R 6 is carboxy, esterifed carboxy or sulfo(lower)alkyl; A 1 , A 2 and A3 are each bond or lower alkylene; and m and n are each an integer of 0 or 1; and their pharmaceutically- acceptable salts have anti-complementary activity and fibrinolytic activity, and are useful as therapeutic agents for immunecomplex diseases or autoimmune diseases such as nephritis, rheumatic diseases, systemic lupus erythematosus, etc. and thrombosis such as cerebral apoplexy, coronary insufficiency, pulmonary embolism.
摘要:
A compound of the formula or its pharmaceutically acceptable salt: wherein
R 1 $ is hydrogen, lower alkyl or lower alkoxy-phenyl, R 2 is hydrogen or lower alkyl, R 3 and R 5 are each hydrogen, or together to form a bond for getting a group of the formula: wherein R 4 and R 6 are each as defined below, R 4 is lower alkyl, R 6 is hydrogen or lower alkyl, R 7 is hydrogen or a certain group, and R 10 is hydrogen or lower alkyl which may have carboxy or esterified carboxy, processes for its preparation and pharmaceutical compositions containing it as an effective ingredient.
摘要:
The present invention provides compounds of the formula:- wherein A is a lower alkylene group; R' is a carboxy, hydroxy, protected hydroxy, lower alkoxycarbonyl, lower alkoxycarbonylamino or lower alkanoyloxy group; R 2 is a hydrogen or halogen atom or a halo (lower) - alkyl group; R 3 is a hydrogen or halogen atom; R 4 is a hydrogen atom or a hydroxy, carboxy, lower alkoxy, lower alkanoyloxy or lower alkoxycarbonyloxy group and R 5 is a hydrogen or halogen atom or R 4 and R 5 together represent the group =CH 2 ; F is the number of double bonds which is equal to 0 or 1 and n is an integer of 0 or 1, with the proviso that when F is 0 then n is 1 and when F is 1 then n is 0; and the pharmaceutically- acceptable salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them. Futhermore, the present invention is concerned with the use of these compounds for the treatment of diabetic cataract and/or neuropathy.
摘要翻译:本发明提供下式的化合物:其中A为低级亚烷基; R 1是羧基,羟基,保护的羟基,低级烷氧基羰基,低级烷氧基羰基氨基或低级烷酰氧基; R 2是氢或卤素原子或卤代(低级) - 烷基; R 3是氢或卤素原子; R 4是氢原子或羟基,羧基,低级烷氧基,低级烷酰氧基或低级烷氧基羰氧基,R 5是氢或卤素原子,或者R 4和R 5一起代表基团= CH 2 ; F是等于0或1的双键数,n是0或1的整数,条件是当F为0时,n为1,当F为1时,n为0; 及其药学上可接受的盐。 本发明还提供了制备这些化合物的方法和含有它们的药物组合物。 此外,本发明涉及这些化合物用于治疗糖尿病性白内障和/或神经病变的用途。
摘要:
The invention relates to compositions comprising one or more of the following compounds designated WS-1627A, WS-1627B, WS-1627C and WS-1627D, or salts thereof:
WS-1627A, WS-1627B and WS-1627D are in fact known antibiotics, but WS-1627C is a new epimer of the antibiotic KA-3093. The compositions are useful both for preventing or treating swine dysentery and as animal growth promotants. There is also provided a process for preparing WS-1627A, WS-1627B, WS-1627C and WS-1 627D which comprises culturing a WS-1627A, WS-1627B, WS-1627C and/or WS-1627D producing strain belonging to the genus Streptomyces in a nutrient medium and recovering the product.
摘要:
The present invention provides compounds of the general formula: wherein R 1 is a hydroxyl or protected hydroxyl group or a carboxyl group or a lower alkoxycarbonyl or benzyloxy radical, R 2 is a hydrogen or halogen atom or a halo(lower)alkyl radical, R 3 is a hydrogen atom, a hydroxyl group or a lower alkoxy radical and A is a lower alkylene radical; and the pharmaceutically acceptable salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them and is also concerned with the use thereof.